IMRA - Imara declined yesterday as its sickle cell treatment appears to be not at par with its peers

Imara (IMRA) closed in red, down 38% yesterday as investors apparently saw the company's sickle cell data lacked benefit when compared to its peers.Data showed that IMR-687 had no meaningful impact on key measures like fetal hemoglobin ((HbF)) or hemoglobin levels when taken by itself. Combination with HU showed slight benefits in F- cells and fetal hemoglobin levels but hemoglobin decreased on average after 24 weeks.Three of eight combination patients had absolute increases in HbF percentage of greater than 1%, with a mean absolute increase in HbF percentage of 4.3% in that subset of patientsGlobal Blood Therapeutics and Novartis already have approved therapies to treat sickle cell patients while one-time treatments from Bluebird bio (BLUE) and Vertex/Crispr (VRTX) (CRSP) have shown promise for potentially curative therapies, raising the bar.SVB Leerink analyst Joe Schwartz defended the company stating that Covid-19 hurt the trial because of missed visits that “potentially undermined the quality of the data”.He

For further details see:

Imara declined yesterday as its sickle cell treatment appears to be not at par with its peers